Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001031062 | SCV001194368 | likely pathogenic | Glycine encephalopathy | 2019-07-05 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Thr830 and p.Val905 amino acid residues in GLDC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27362913, 16450403, 26179960, 28244183). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals with GLDC-related conditions. This variant is a gross deletion of the genomic region encompassing exons 21-25 of the GLDC gene. The 5' boundary is likely confined to intron 21. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. |